Search Results
Jul 28, 2026, 09:30 ET Nitinotes Announces First Study Procedures at Orlando Health in the EASE™ IDE Trial
Gastroplasty (ESG), a minimally invasive procedure for the treatment of obesity. The multicenter study is designed to support a future U.S. Food and Drug Administration (FDA) marketing submission."Dr. Teixeira and Dr. Galvao Neto are among the leaders advancing minimally invasive obesity treatment,"
More news about: Nitinotes
Jul 28, 2026, 09:30 ET Nitinotes Announces First Study Procedures at Orlando Health in the EASE™ IDE Trial
Gastroplasty (ESG), a minimally invasive procedure for the treatment of obesity. The multicenter study is designed to support a future U.S. Food and Drug Administration (FDA) marketing submission."Dr. Teixeira and Dr. Galvao Neto are among the leaders advancing minimally invasive obesity treatment,"
More news about: Nitinotes
Jul 28, 2026, 09:16 ET RAAP Releases New Policy Study: "Follow the UPL"
As states continue to look for ways to address prescription drug costs, nine have established active PDABs, with Colorado and Maryland becoming the first to set UPLs — on the arthritis biologic Enbrel and the diabetes drug Jardiance, respectively. The study, researched and written by Jennifer
More news about: Rare Access Action Project (RAAP)
Jul 28, 2026, 09:00 ET AllyGPO Appoints Dustin Faircloth President of AllyOncology
community-based practices with advanced, AI-powered technologies and proprietary smart practice tools to navigate the complex specialty drug market. By combining comprehensive drug contracting services with intelligent inventory management, predictive analytics, and hands-on operational support, we deliver meaningful,
More news about: AllyGPO
Jul 28, 2026, 09:00 ET Ambrosia Biosciences Enhances Clinical and Scientific Expertise with Chief Medical Officer and Scientific Advisory Board Appointments
Biosciences Inc. Ambrosia Biosciences Inc. is a privately held drug discovery company developing next-generation oral small molecule therapies for obesity and other metabolic disorders. By integrating structurally-enabled drug design with in-house medicinal chemistry and biology capabilities, Ambrosia
More news about: Ambrosia Biosciences
Jul 28, 2026, 09:00 ET Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures
toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).
More news about: Aurenar
Jul 28, 2026, 08:36 ET IntelliGenome Appoints Yu Shing Bio-Tech as Exclusive Distributor for CRISPR-TB in Taiwan
Yu Shing Bio-Tech will commercialize IntelliGenome's CE-IVDD CRISPR-TB blood test in Taiwan, support regulatory registration with the Taiwan Food and Drug Administration (TFDA), and collaborate with leading clinical institutions to advance tuberculosis diagnostics throughout the country. "Taiwan
More news about: IntelliGenome
Jul 28, 2026, 08:21 ET CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs
innovative drug discovery company developing transformative precision medicines for broader populations of cancer patients focusing on lineage biology. The company is advancing a portfolio of innovative oncology programs and leverages deep expertise in cancer biology, precision medicine, and drug development
More news about: CORE Biomedicine
Jul 28, 2026, 08:15 ET Parker Waichman Applauds Health Canada and Australia for Strengthening NAION Safety Guidance for Certain GLP-1 Medications
or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice.Contact
More news about: Parker Waichman LLP
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
a novel treatment option for MSA patients worldwide.YA-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), alongside Orphan Drug Designation (ODD) from regulatory agencies in the U.S., Japan, and the European Union.MSA is a rare, rapidly progressive,
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
a novel treatment option for MSA patients worldwide.YA-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), alongside Orphan Drug Designation (ODD) from regulatory agencies in the U.S., Japan, and the European Union.MSA is a rare, rapidly progressive,
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:08 ET CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics
We are delighted to witness the company's fast-growing trajectory. We look forward to collaborating with CORE Biomedicine to advance its cutting-edge drug pipeline and address unmet medical needs for global patients by delivering better clinical benefits." About CORE Biomedicine
More news about: CORE Biomedicine
Jul 28, 2026, 08:05 ET NextPlat Delivers Mid-Year 2026 Shareholder Update Confirming Strong Growth and Profitability Outlook
driven by factors including an increased focus on contracted services, such as supporting entities participating in the U.S. Government's 340B discount drug pricing program.Early second quarter results indicate that higher-margin 340B prescriptions have continued to increase rapidly, rising over
More news about: NextPlat Corp.
Jul 28, 2026, 08:00 ET Torrey Pines Medicine Secures Angel Round to Advance Next-Generation Ultra-Long-Acting Peptide Therapeutics
Laboratory, Peking University, and HEC Pharma. The team's comprehensive capabilities span the entire drug discovery and development lifecycle, including target discovery, AI-assisted drug design, drug screening (pharmacology, pharmacokinetics, CMC development), preclinical evaluation, IND regulatory filings,
More news about: Torrey Pines Medicine
Jul 28, 2026, 08:00 ET PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology
Pharmaceuticals, LLC, the developer, manufacturer, and patent owner, today announced that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent No. 12,667,554 B1 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for HemiClor.
More news about: PRM Pharma, LLC
Jul 28, 2026, 08:00 ET BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
neuroprotection.NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis and has received Orphan Drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency. A Phase 3 trial in ALS has been completed, and a Phase 3b trial is set to launch
More news about: BrainStorm Cell Therapeutics Inc.
Jul 28, 2026, 08:00 ET Cipla Receives U.S. FDA Approval for Generic Advair Diskus®
subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"), today announced that Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths—100/50
More news about: Cipla Limited
Jul 28, 2026, 07:01 ET SamaCare Releases Q2 2026 Market Access Benchmarks for Medical Benefit Drugs
of access friction. Retina was the exception, with initiation approval rates slightly exceeding continuation approval rates during the quarter.Drug-level analysis also showed meaningful variation by individual medication and therapy type. Therapies with more complex access pathways, including select
More news about: SamaCare
Jul 28, 2026, 07:00 ET Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
sublingual absorption and reduced first-pass hepatic metabolism, designed to maximize drug exposure within the brain.Galmed believes that the development of a clinically characterized SCD1 inhibitor with a CNS-optimized drug delivery formulation represents a differentiated strategy in a therapeutic area
More news about: Galmed Pharmaceuticals Ltd.
Jul 28, 2026, 07:00 ET Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
including with the Emergency Task Force expert group of the African Medicines Agency (equivalent to EMA/FDA and designed to coordinate and harmonize drug approvals across Africa), the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Scientific
More news about: RedHill Biopharma Ltd.
Jul 28, 2026, 06:36 ET REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses
checkpoint receptor on T-cells. Specifically, Regeneron was testing Fianlimab in combination with Libtayo in a Phase III study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma.Regeneron told investors that it had "a lot of hope and confidence" that
More news about: Bleichmar Fonti & Auld LLP
Jul 28, 2026, 06:00 ET CENTENE ANNOUNCES BOARD OF DIRECTORS CHANGES
and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace. Centene uses its investor relations website to publish important
More news about: Centene Corporation
Jul 28, 2026, 06:00 ET CENTENE CORPORATION REPORTS SECOND QUARTER 2026 RESULTS
1,026,900Medicare Prescription Drug Plan (PDP)8,803,000
More news about: Centene Corporation
Jul 28, 2026, 05:15 ET Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%
(Dr.) S.S. Sehgal said, "Drug absorption studies are among the most important stages in oral drug development because they help scientists understand how efficiently a medicine is likely to be absorbed before it progresses to advanced stages of research. The conventional drug absorption equipment offer
More news about: Chandigarh University
Jul 28, 2026, 05:00 ET Cognizant launches EMEA AI Unit to help enterprises scale agentic AI adoption
experience and margin protection. It is also working with a global pharmaceutical leader to reimagine R&D operations through multi-agent systems spanning drug discovery, clinical trial design and regulatory preparation.The EMEA AI Unit reflects Cognizant's AI Builder approach by combining people, platforms
More news about: Cognizant Technology Solutions Corporation